Literature DB >> 17516146

Factor XIII gene V34L mutation in the Lebanese population: another unique feature in this community?

Rami A R Mahfouz1, Amira S Sabbagh, Dina M R Shammaa, Zaher K Otrock, Ghazi S Zaatari, Ali T Taher.   

Abstract

We studied the distribution of the Factor XIII gene V34L polymorphism in a sample of healthy Lebanese individuals to assess its prevalence and compare it with other populations. Factor XIII genotypes were determined using the Cardiovascular Disease (CVD) StripAssay (ViennaLab, Austria), which is based on a Polymerase Chain Reaction-Reverse hybridization technique. DNA from 205 unrelated healthy donors from our HLA database was used. The prevalence of Wild type, heterozygous, and homozygous genotypes was found to be 74.2%, 22.4%, and 3.4% respectively. The sampled Lebanese population showed that the prevalence of V34L carriers (25.8%) was lower than Caucasians in general (44.3%) and, interestingly, with a low allele frequency of 0.14 similar to that in Blacks and South Asians. This first report from Lebanon sheds light on an additional unique genetic feature of this population and will prospectively serve as a baseline statistical data for future investigations of the prevalence of Factor XIII V34L mutation in association with various clinical entities notably cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516146     DOI: 10.1007/s11033-007-9096-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  39 in total

1.  The FXIII Val 34 Leu mutation and the risk of venous thrombosis.

Authors:  M Alhenc-Gelas; J L Reny; M L Aubry; M Aiach; J Emmerich
Journal:  Thromb Haemost       Date:  2000-12       Impact factor: 5.249

2.  Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography.

Authors:  D Warner; M W Mansfield; P J Grant
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

3.  High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation?

Authors:  A Taher; I Khalil; A Shamseddine; F El-Ahdab; A Bazarbachi
Journal:  Thromb Haemost       Date:  2001-08       Impact factor: 5.249

4.  Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk.

Authors:  Bernard C B Lim; Robert A S Ariëns; Angela M Carter; John W Weisel; Peter J Grant
Journal:  Lancet       Date:  2003-04-26       Impact factor: 79.321

5.  Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation.

Authors:  T A Trumbo; M C Maurer
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

6.  Genetic polymorphisms and coronary artery disease in the south of France.

Authors:  I Canavy; M Henry; P E Morange; L Tiret; O Poirier; A Ebagosti; M Bory; I Juhan-Vague
Journal:  Thromb Haemost       Date:  2000-02       Impact factor: 5.249

7.  Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria.

Authors:  W Renner; H Köppel; C Hoffmann; K Schallmoser; O Stanger; H Toplak; T C Wascher; E Pilger
Journal:  Thromb Res       Date:  2000-07-01       Impact factor: 3.944

8.  Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis.

Authors:  Philip S Wells; Josdalyne L Anderson; Dimitrios K Scarvelis; Steve P Doucette; France Gagnon
Journal:  Am J Epidemiol       Date:  2006-06-01       Impact factor: 4.897

9.  No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.

Authors: 
Journal:  Circulation       Date:  2003-03-04       Impact factor: 29.690

10.  Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease?

Authors:  Georg Endler; Marion Funk; Daniela Haering; Wolfgang Lalouschek; Wilfried Lang; Merdad Mirafzal; Oswald Wagner; Christine Mannhalter
Journal:  Br J Haematol       Date:  2003-01       Impact factor: 6.998

View more
  6 in total

1.  Impact of FXIII-A Val34Leu polymorphism on coronary artery disease in Croatian patients.

Authors:  Ana Bronić; Goran Ferencak; Renata Zadro; Ana Stavljenić-Rukavina; Robert Bernat
Journal:  Mol Biol Rep       Date:  2007-09-27       Impact factor: 2.316

2.  The association between cardiovascular disease gene mutations and recurrent pregnancy loss in the Lebanese population.

Authors:  Hanadi El Achi; Johnny Awwad; Sarah Abou Daya; Sahar Halabi; Sandra Damianos; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2018-07-04       Impact factor: 2.316

3.  Association of methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genetic polymorphisms with occlusive artery disease and deep venous thrombosis in Macedonians.

Authors:  Igor Spiroski; Sashko Kedev; Slobodan Antov; Todor Arsov; Marija Krstevska; Sloboda Dzhekova-Stojkova; Stojanka Kostovska; Dejan Trajkov; Aleksandar Petlichkovski; Ana Strezova; Olivija Efinska-Mladenovska; Mirko Spiroski
Journal:  Croat Med J       Date:  2008-02       Impact factor: 1.351

4.  Evaluation of Factor V G1691A, prothrombin G20210A, Factor XIII V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G genotype frequencies of patients subjected to cardiovascular disease (CVD) panel in south-east region of Turkey.

Authors:  Serdar Oztuzcu; Sercan Ergun; Mustafa Ulaşlı; Gülper Nacarkahya; Yusuf Ziya Iğci; Mehri Iğci; Recep Bayraktar; Ali Tamer; Ecir Ali Çakmak; Ahmet Arslan
Journal:  Mol Biol Rep       Date:  2014-02-15       Impact factor: 2.316

5.  Significance of the use of the ViennaLab "Cardiovascular Disease panel" (CVD) Assay as a reflex test for the "Factor V/II/MTHFR Assay".

Authors:  Rouba Hoteit; Fatmeh Abbas; Ahmad Antar; Rabab Abdel Khalek; Dina Shammaa; Rami Mahfouz
Journal:  Meta Gene       Date:  2013-11-19

6.  High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.

Authors:  Jeanne d'Arc AlBacha; Mira Khoury; Charbel Mouawad; Katia Haddad; Samar Hamoui; Albert Azar; Ziad Fajloun; Nehman Makdissy
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.